文献速递精神分裂症与精神病性障碍会诊联络精神医学

利拉鲁肽治疗精神分裂症谱系障碍患者氯氮平或奥氮平所致糖尿病前期及超重/肥胖的随机临床试验

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2017-01-01

这项在丹麦2个中心开展的随机双盲试验纳入103例接受稳定氯氮平或奥氮平治疗、超重或肥胖且糖尿病前期的精神分裂症谱系障碍患者,比较每日皮下注射利拉鲁肽与安慰剂16周的效果。利拉鲁肽组糖耐量改善更显著,63.8%恢复至正常糖耐量(安慰剂组16.0%),并降低体重、腰围、收缩压、内脏脂肪和低密度脂蛋白。

要点

  • 利拉鲁肽16周治疗使63.8%糖尿病前期患者糖耐量恢复正常,需治疗人数为2。
  • 利拉鲁肽较安慰剂显著降低体重5.3 kg,并改善腰围、收缩压、内脏脂肪和低密度脂蛋白。
  • 不良事件主要涉及胃肠道,提示需监测耐受性。

核心结论

  • 利拉鲁肽显著改善接受氯氮平或奥氮平治疗的精神分裂症谱系障碍患者的糖耐量、体重及心血管代谢紊乱。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,在丹麦2个临床中心纳入103例合格的精神分裂症谱系障碍患者。
  • 参与者接受稳定氯氮平或奥氮平治疗,超重或肥胖且合并糖尿病前期,随机接受每日皮下注射利拉鲁肽或安慰剂16周。
  • 数据收集时间为2013年5月1日至2016年2月25日,97例纳入有效性分析。

主要发现

  • 利拉鲁肽组糖耐量较安慰剂组显著改善(P < .001)。
  • 利拉鲁肽组63.8%患者恢复至正常糖耐量,安慰剂组为16.0%(P < .001;需治疗人数为2)。
  • 利拉鲁肽较安慰剂降低体重-5.3 kg(95% CI, -7.0至-3.7 kg),并降低腰围、收缩压、内脏脂肪和低密度脂蛋白。
  • 利拉鲁肽相关不良事件主要累及胃肠道。

关键数值与推荐

  • 主要终点为75 g口服葡萄糖耐量试验评估的糖耐量变化。
  • 次要终点包括体重及心血管代谢参数变化。
  • 利拉鲁肽组恢复至正常糖耐量比例为63.8%,安慰剂组为16.0%(P < .001;需治疗人数为2)。

临床怎么用

  • 对于氯氮平或奥氮平治疗中合并糖尿病前期及超重/肥胖的精神分裂症谱系障碍患者,可考虑加用利拉鲁肽以改善糖耐量及心血管代谢指标。
  • 使用利拉鲁肽时需关注胃肠道不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Compared with the general population, patients with schizophrenia have a 2- to 3-fold higher mortality rate primarily caused by cardiovascular disease. Previous interventions designed to counteract antipsychotic-induced weight gain and cardiometabolic disturbances reported limited effects. OBJECTIVES: To determine the effects of the glucagon-like peptide-1 receptor agonist liraglutide added to clozapine or olanzapine treatment of schizophrenia spectrum disorders. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical double-blind trial enrolled participants at 2 clinical sites in Denmark. Of 214 eligible participants with a schizophrenia spectrum disorder, 103 were randomized to liraglutide or placebo. Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes. Data were collected from May 1, 2013, through February 25, 2016. INTERVENTIONS: Treatment for 16 weeks with once-daily subcutaneous injection of liraglutide or placebo. Trial drug therapy was titrated during the first 2 weeks of the study. MAIN OUTCOMES AND MEASURES: The primary end point was change in glucose tolerance estimated by a 75-g oral glucose tolerance test result. Secondary end points included change in body weight and cardiometabolic parameters. RESULTS: Of the 103 patients undergoing randomization (60 men [58.3%] and 43 women [41.7%]), 97 were included in the efficacy analysis, with a mean (SD) age of 42.5 (10.5) years and mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) of 33.8 (5.9). The liraglutide and placebo groups had comparable characteristics (mean [SD] age, 42.1 [10.7] vs 43.0 [10.5] years; 30 men in each group; mean [SD] body mass index, 33.7 [5.1] vs 33.9 [6.6]). A total of 96 randomized participants (93.2%) completed the trial. Glucose tolerance improved in the liraglutide group compared with the placebo group (P < .001). Altogether, 30 liraglutide-treated participants (63.8%) developed normal glucose tolerance compared with 8 placebo-treated participants (16.0%) (P < .001; number needed to treat, 2). Body weight decreased with liraglutide compared with placebo (-5.3 kg; 95% CI, -7.0 to -3.7 kg). Reductions in waist circumference (-4.1 cm; 95% CI, -6.0 to -2.3 cm), systolic blood pressure (-4.9 mm Hg; 95% CI, -9.5 to -0.3 mm Hg), visceral fat (-250.19 g; 95% CI, -459.9 to -40.5 g), and low-density lipoprotein levels (-15.4 mg/dL; 95% CI, -23.2 to -7.7 mg/dL) occurred with liraglutide compared with placebo. Adverse events with liraglutide affected mainly the gastrointestinal tract. CONCLUSIONS AND RELEVANCE: Liraglutide significantly improved glucose tolerance, body weight, and cardiometabolic disturbances in patients with schizophrenia spectrum disorders treated with clozapine or olanzapine. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01845259.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017. PMID: 28601891. doi:10.1001/jamapsychiatry.2017.1220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。